Skip to main content
The NCI Community Hub will be retiring in May 2024. For more information please visit the NCIHub Retirement Page:https://ncihub.cancer.gov/groups/ncihubshutdown/overview
close

Resources: All

Find a resource
  1. nanoparticles x
  2. nanoparticle x
  3. nanoinformatics x
  4. standardsportal x
  1. Standards Portal Vocabulary DataView

    15 Mar 2014 | Contributor(s): Sherri de Coronado, Denise Warzel, Ann Christine Catlin, Sumudinie fernando

    The DataView for terminology referenced/used by the CDEs and CRFs currently contained in the Standards PortalThe DataView on this resource page can be used to browse, search, explore and download the NCI concepts for vocabulary referenced by the CDEs and CRFs uploaded to the Standards Portal....

  2. Standards Portal CDEs Complete View

    15 Mar 2014 | Contributor(s): Denise Warzel, Ann Christine Catlin, Sumudinie fernando

    This DataView on this resource page is used to explore the Standards Portal CDEsUse the DataView provided on this resource page to navigate, browse, search, explore and download the complete set of columns for NCI common data elements standards at the Hub. These CDEs are brought to the Hub for...

  3. NCI Standard CRFs

    15 Mar 2014 | Teaching Materials | Contributor(s): Denise Warzel, Ann Christine Catlin, Sumudinie fernando

    Working in conjunction with NCI has developed a collection of Standard Case Report Forms (CRFs) for use in developing new protocols. The project and its status are described here. The reuse of sections from standard CRFs helps to ensure that data collected in different studies is compatible and...

  4. Performance Status Scoring : a standards portal resource

    15 Mar 2014 | Teaching Materials | Contributor(s): Ann Christine Catlin, Sumudinie fernando, Denise Warzel, Angela Kummerow

    The scoring scale used may depend on patient population, disease, study goals and other criteria. Many definitions of the scale scoring do not match the standard.What is Performance Status?Performance status attempts to quantify the general well-being of cancer and other patients. The score...

  5. Adverse Events Terminology Standards, Data Elements and Case Report Forms

    15 Mar 2014 | Teaching Materials | Contributor(s): Sherri de Coronado, Ann Christine Catlin, Sumudinie fernando, Denise Warzel

    Standards for coding, naming and grading adverse events (AEs) in cancer clinical trials include both cancer-focused and broader systems that all result from collaboration among academic, governmental, and pharmaceutical industry clinical investigators. They are all based on the need for...

  6. TCGA Common Data Elements

    15 Mar 2014 | Teaching Materials | Contributor(s): Ann Christine Catlin, Sumudinie fernando, Denise Warzel

    TCGA Common Data ElementsTCGA version 2.6 CDEs are the standard elements that were used in validation of clinical data in the TCGA 2.6 data files. The data files are available for download at the Data Matrix. This resource page at the NCIP HUB presents the CDEs for easy search and discovery....

  7. caNanoLab: data sharing to expedite the use of nanotechnology in biomedicine

    13 Dec 2013 | Publications | Contributor(s): Sharon Gaheen, George W Hinkal, Stephanie A Morris, Michal Lijowski, Mervi Heiskanen, Juli Klemm

    The use of nanotechnology in biomedicine involves the engineering of nanomaterials to act as therapeutic carriers, targeting agents and diagnostic imaging devices. The application of nanotechnology in cancer aims to transform early detection, targeted therapeutics and cancer prevention and...

  8. caNanoLab: data sharing to expedite the use of nanotechnology in biomedicine

    13 Dec 2013 | Publications | Contributor(s): Sharon Gaheen, George W Hinkal, Stephanie A Morris, Michal Lijowski, Mervi Heiskanen, Juli Klemm

    The use of nanotechnology in biomedicine involves the engineering of nanomaterials to act as therapeutic carriers, targeting agents and diagnostic imaging devices. The application of nanotechnology in cancer aims to transform early detection, targeted therapeutics and cancer prevention and...